Philippines - English - FDA (Food And Drug Administration)

(for) dia chemie; importer: i. e. medica, inc.; distributor: zyre pharmaceuticals corporation - cefuroxime sodium - powder for injection (im/iv) - 750 mg

Philippines - English - FDA (Food And Drug Administration)

medethix, inc.; distributor: zyre pharmaceuticals corporation - 5% amino acids , 5% sorbitol - solution for itravenous infusion for injection - (see formulation on reverse side)

Philippines - English - FDA (Food And Drug Administration)

stratgen healthcare pvt. ltd.; importer: i.e. medica inc.; distributor: zyre pharmaceuticals corporation - cefuroxime (as sodium) - powder for injection (im/iv) - 750 mg

United States - English - NLM (National Library of Medicine)

incyte corporation - pemigatinib (unii: y6bx7bl23k) (pemigatinib - unii:y6bx7bl23k) - pemazyre is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or other rearrangement as detected by an fda-approved test [see dosage and administration (2.1)] . this indication is approved under accelerated approval based on overall response rate and duration of response [see clinical studies (14.1)].  continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). pemazyre is indicated for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (mlns) with fibroblast growth factor receptor 1 (fgfr1) rearrangement. none. risk summary based on findings in an animal study and its mechanism of action, pemazyre can cause fetal harm or loss of pregnancy when administered to a pregnant woman [see clinical pharmacology ( 12.1 )] . there are no available data on the use of pemazyre in preg

European Union - English - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - pemigatinib - cholangiocarcinoma - antineoplastic agents - pemazyre monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed  after at least one prior line of systemic therapy.

Israel - English - Ministry of Health

medison pharma ltd - pemigatinib - tablets - pemigatinib 13.5 mg - pemigatinib - pemazyre is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or other rearrangement as determined by a validated test.

Israel - English - Ministry of Health

medison pharma ltd - pemigatinib - tablets - pemigatinib 4.5 mg - pemigatinib - pemazyre is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or other rearrangement as determined by a validated test.

Israel - English - Ministry of Health

medison pharma ltd - pemigatinib - tablets - pemigatinib 9 mg - pemigatinib - pemazyre is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or other rearrangement as determined by a validated test.

Philippines - English - FDA (Food And Drug Administration)

zyre pharmaceuticals corporation; distributor: zyre pharmaceuticals corporation - ciprofloxacin - solution for injection (iv) - 200mg/100ml (2mg/ml)

Philippines - English - FDA (Food And Drug Administration)

zyre pharmaceuticals corporation; distributor: zyre pharmaceuticals corporation - ceftriazone (as sodium) - powder for injection - 1g